Answers are grounded in this paper and cite their sources.
Rationale: Rapidly progressive interstitial lung disease (RP-ILD) is a severe complication of anti- melanoma differentiation associated gene 5 (MDA5) antibody-positive dermatomyositis and has an extremely poor prognosis. Patient concerns: We describe the case of a 62-year-old Japanese male with progressive hypoxemia. Laboratory examinations revealed elevated levels of serum ferritin, KL-6, myogenic enzymes, liver enzyme, inflammatory markers and Anti-MDA5-antibody positivity. Chest computed tomography revealed consolidation along the bronchovascular bundle with air bronchograms, predominantly in the inferior lobe of both lungs. Diagnosis: The patient was diagnosed as anti-MDA5 antibody-positive RP-ILD. Interventions: Respiratory failure continued to worsen even after conventional therapy with glucocorticoids and intravenous cyclophosphamide. Due to the severity of his symptoms, tofacitinib was used in combination with tacrolimus, rituximab, and plasma exchange. Outcomes: The severity of his respiratory symptoms dramatically decreased and he was discharged without the need for supplemental oxygen. Lessons: This case suggests that multi-target immunosuppressive therapy including tofacitinib can be useful for anti-MDA5 antibody-positive RP-ILD in patients with poor prognostic factors.
No takes yet. Share an insight, caveat, or question.
Machiyama et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: